|Bid||12.50 x 0|
|Ask||16.40 x 0|
|Day's Range||13.20 - 15.00|
|52 Week Range||10.00 - 209.80|
|Beta (5Y Monthly)||-2.57|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sept 29, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Every investor in Synairgen plc ( LON:SNG ) should be aware of the most powerful shareholder groups. With 36% stake...
SOUTHAMPTON, England, October 04, 2022--Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta to treat or prevent severe viral lung infections, today announces topline data for participants treated with SNG001 in the US National Institutes of Health (NIH)/ AIDS Clinical Trials Group (ACTG)-led ACTIV-2 Phase 2 adaptive platform trial for COVID-19.